• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Astellas Pharma Inc. - Articles and news items

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

CHMP issues positive opinion for Xtandi label update

Industry news / 8 April 2016 / Victoria White, Digital Content Producer

The CHMP has recommended approval of a type II variation to include data from the TERRAIN trial of Xtandi (enzalutamide) versus bicalutamide…

Phase III enzalutamide trial initiated in mHSPC

Industry news / 29 March 2016 / Victoria White

The ARCHES trial will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in mHSPC patients…

Study data published for Cresemba in patients with mucormycosis

Industry news / 9 March 2016 / Victoria White

Cresemba (isavuconazonium sulfate) is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis…

James Robinson named as President, Americas Operations for Astellas

Industry news / 9 February 2016 / Victoria White

Effective from 1st April 2016, Robinson will have responsibility for the company’s operations in North and South America…

STRIVE results for enzalutamide in CRPC published

Industry news / 27 January 2016 / Victoria White

The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide…

NICE recommends five new therapies

Industry news / 27 January 2016 / Victoria White

NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS…

Study results for enzalutamide vs. bicalutamide in prostate cancer published

Industry news / 14 January 2016 /

The TERRAIN study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival for enzalutamide compared to bicalutamide…

Astellas announces updated results for gilteritinib in AML

Industry news / 7 December 2015 / Victoria White

This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with at least 80 mg gilteritinib (ASP2215)…

LEO Pharma to acquire global dermatology portfolio from Astellas

Industry news / 11 November 2015 / Victoria White

The transaction will be the largest in LEO Pharma’s more than 100-year history in terms of incremental turnover…

Astellas to acquire Ocata Therapeutics for $379 million

Industry news / 10 November 2015 / Victoria White

Acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy…

First patient dosed in Phase 3 trial of gilteritinib in AML

Industry news / 28 October 2015 / Victoria White

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as tyrosine kinase domain, two common types of FLT3 mutations that are seen in AML…